

NILOTINIB EFFECTIVE DATE: 2015-05-16

1 Product and Company Identification

1.1 Product Name: Nilotinik

1.2 Product Identifier: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-

3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

1.3 Catalog Number: 73302, 73304

1.4 Product Use: Laboratory Chemical

1.5 Manufacturer/Supplier: STEMCELL Technologies

Suite 500-1618 Station Street

Vancouver, British Columbia V6A 1B6 Canada

1.6 In Case of Emergency Call: 1-800-667-0322

2 Hazards Identification

2.1 Classification of the substance or mixture

Target Organ Systemic Toxicity (repeated exposure), Category 1 Aquatic Toxicity (Chronic), Category 4

2.2 Label elements

Pictogram



Signal word Danger

Hazard statement(s)

H372 Causes damage to organs {liver, kidney} through prolonged or

repeated exposure.

H413 May cause long lasting harmful effects to aquatic life.

Precautionary statement(s)

P260 Do not breathe {dust/fume/gas/mist/vapours/spray}.

P264 Wash {hands} thoroughly after handling.

P273 Avoid release to the environment.

P270 Do not eat, drink or smoke when using this product.
P314 Get medical attention/advice if you feel unwell.

2.3 Other hazards No data available

3 Composition / Information on Ingredients

3.1 Substances

Synonyms 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)

phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide:

AMN107; Tasigna

Molecular formula $C_{28}H_{22}F_3N_7O$

73302_73304-SDS_GHS Page 1 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

Molecular weight

529.5

Hazardous Components (Chemical Name)	CAS#	Concentration	EC#
4-methyl-N-[3-(4-methylimidazol-1-yl)-5- (trifluoromethyl)phenyl]-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]benzamide	641571-10-0	100%	700-544-5

4 First Aid Measures

4.1 Description of first aid measures

4.1.1 If inhaled

Remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Get immediate medical attention.

4.1.2 In case of skin contact

Immediately wash skin with soap and plenty of water for at least 15 minutes. Remove contaminated clothing. Get medical attention if symptoms occur. Wash clothing before reuse.

4.1.3 In case of eye contact

Hold eyelids apart and flush eyes with plenty of water for at least 15 minutes. Have eyes examined and tested by medical personnel.

4.1.4 If swallowed

Wash out mouth with water provided person is conscious. Never give anything by mouth to an unconscious person. Get medical attention. Do NOT induce vomiting unless directed to do so by medical personnel.

4.2 Most important symptoms and effects, both acute and delayed

The toxicological properties of this product have not been fully evaluated.

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5 Fire Fighting Measures

5.1 Extinguishing Media

5.1.1 Suitable Extinguishing Media

Use alcohol-resistant foam, carbon dioxide, water, or dry chemical spray.

Use water spray to cool fire-exposed containers.

5.1.2 Unsuitable Extinguishing Media

A solid water stream may be inefficient.

5.2 Special hazards arising from the substance or mixture

5.2.1 Flammable Properties and Hazards

No data available

5.2.2 Flash Pt

No data available

5.2.3 Autoignition Pt

73302_73304-SDS_GHS Page 2 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

No data available

5.2.4 Explosive Limits

LEL: No data available UEL: No data available

5.2.5 Hazardous Combustion Products

No data available

5.3 Fire Fighting Instructions

As in any fire, wear self-contained breathing apparatus pressure-demand (NIOSH approved or equivalent), and full protective gear to prevent contact with skin and eyes.

6 Accidental Release Measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid raising and breathing dust, and provide adequate ventilation.

As conditions warrant, wear a NIOSH approved (or equivalent) self-contained breathing apparatus, or respirator, and appropriate personal protection (rubber boots, safety goggles, and heavy rubber gloves).

6.2 Environmental precautions

Take steps to avoid release into the environment, if safe to do so.

6.3 Methods and materials for containment and cleaning up

Contain spill and collect, as appropriate.

Transfer to a chemical waste container for disposal in accordance with local regulations.

7 Handling and Storage

7.1 Precautions for safe handling

Avoid breathing dust/fume/gas/mist/vapours/spray.

Avoid prolonged or repeated exposure.

7.2 Conditions for safe storage

Keep container tightly closed.

Store in accordance with information listed on the product insert.

8 Exposure Controls/Personal Protection

8.1 Exposure limits

Component	CAS#	Value	Control parameters
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide	641571-10-0	No data available	No data available

8.2 Engineering controls

Use process enclosures, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits.

73302_73304-SDS_GHS Page 3 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

8.3 Personal protective equipment

8.3.1 Eye/face protection

Safety glasses

8.3.2 Skin protection

Compatible chemical-resistant gloves

Lab coat

8.3.3 Respiratory protection

NIOSH (US) or CEN (EU) approved respirator, as conditions warrant.

8.3.4 General hygiene considerations

Do not take internally.

Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.

Wash thoroughly after handling.

8.3.5 Environmental exposure controls

No data available

9 Physical and Chemical Properties

9.1 Information on basic physical and chemical properties

Appearance A crystalline solid Odour No data available No data available Odour threshold На No data available Melting point/freezing point No data available No data available Boiling point/boiling range Flash point No data available No data available Evaporation rate Flammability (solid, gas) No data available Upper/lower flammability or explosive limits No data available Vapour pressure No data available Vapour density No data available Relative density No data available

Solubility ~3 mg/mL in DMF; ~10 mg/mL in DMSO

Partition coefficient: n-octanol/water

Auto-ignition temperature

Decomposition temperature

Viscosity

No data available

No data available

No data available

10 Stability and Reactivity

10.1 Reactivity No data available

10.2 Chemical stability Stable

73302_73304-SDS_GHS Page 4 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

10.3 Possibility of hazardous reactions No data available

10.4 Conditions to avoidNo data available

10.5 Incompatible materials Strong oxidizing agents

10.6 Hazardous decomposition products Carbon dioxide

Carbon monoxide Nitrogen oxides

11 Toxicological Information

11.1 Acute toxicity

Oral: Oral TDLO (woman): 160 mg/kg/10D (intermittent); Oral TDLO (rat):

140 mg/kg/1W (intermittent)

Inhalation: No data available
Dermal: No data available
Other: No data available

11.2 Skin corrosion/irritation

No data available

11.3 Serious eye damage/eye irritation

No data available

11.4 Respiratory and/or skin sensitization

No data available

11.5 Germ cell mutagenicity

No data available

11.6 Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is

identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is

identified as a carcinogen or potential carcinogen by OSHA.

11.7 Reproductive toxicity

No data available

11.8 Specific target organ toxicity - single exposure

No data available

11.9 Specific target organ toxicity - repeated exposure

No data available

11.10 Aspiration hazard

No data available

11.11 Potential health effects

Inhalation: Material may be irritating to the mucous membranes and upper respiratory tract.

May be harmful by inhalation. May cause respiratory system irritation.

Ingestion: May be harmful by ingestion.

73302_73304-SDS_GHS Page 5 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

Skin: May be harmful by skin absorption. May cause skin irritation.

Eyes: May cause eye irritation.

11.12 Signs and symptoms of exposure

Causes damage to liver and kidney through prolonged or repeated exposure.

May cause long lasting harmful effects to aquatic life.

Investigated as a drug.

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

11.13 RTECS # CV5581770

12 Ecological Information

12.1 Toxicity Avoid release into the environment.

Runoff from fire control or dilution water may cause

pollution.

12.2 Persistence and degradability
12.3 Bioaccumulative potential
12.4 Mobility in soil
12.5 Other adverse effects
No data available
No data available
No data available

13 Disposal Considerations

13.1 Waste disposal method

Dispose in accordance with local, provincial/state, and federal regulations.

13.2 Contaminated packaging

Dispose of as unused product.

14 Transport Information

14.1 UN number No data available

14.2 UN proper shipping name DOT Not dangerous goods

ADR/RID Not dangerous goods IMDG Not dangerous goods IATA Not dangerous goods

14.3 Transport hazard class(es) No data available

14.4 Packing group No data available

14.5 Environmental hazards No data available

14.6 Special precautions No data available

15 Regulatory Information

15.1 US EPA SARA Title III

73302_73304-SDS_GHS Page 6 of 7



NILOTINIB EFFECTIVE DATE: 2015-05-16

Hazardous Components (Chemical Name)	CAS#	Sec.302 (EHS)	Sec.304 RQ	Sec.313 (TRI)
4-methyl-N-[3-(4-methylimidazol-1-yl)-5- (trifluoromethyl)phenyl]-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]benzamide	641571-10-0	No	No	No

15.2 Other US EPA or State Lists

Hazardous Components (Chemical Name)	CAS#	CAA HAP, ODC	CWA NPDES	TSCA	CA PROP.65
4-methyl-N-[3-(4-methylimidazol-1-yl)-5- (trifluoromethyl)phenyl]-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]benzamide	641571-10-0	No	No	No	No

15.3 EU

This SDS was prepared in accordance with Regulation (EC) No.1272/2008.

15.4 Canada

Not WHIMIS Controlled.

This SDS was prepared in accordance with Hazardous Products Regulations (HPR) and WHMIS 2015.

16 Other Information

16.1 Prepared by: Quality Control, STEMCELL Technologies Inc.

16.2 Revision: N/A

16.3 Notice: The above information is believed to be correct but does not purport to be all

inclusive and shall be used only as a guide. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product. The information contained in this Safety Data Sheet (SDS) is current as of the Effective Date shown in this document and may be subject to

amendment by STEMCELL Technologies Inc.

16.4 Disclaimer: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT INTENDED FOR

HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES.

73302_73304-SDS_GHS Page 7 of 7